Skip to main content Skip to section navigation Skip to footer
Lexaria Bioscience Corp.Lexaria BioscienceLexaria Bioscience
Lexaria Bioscience Corp.

NASDAQ:LEXX; NASDAQ WARRANT:LEXXW

  • Home
  • About
    • Management
    • Board of Directors
    • Advisors & Consultants
  • Technology
    • Overview
    • Commercial Applications
    • Research
    • Patent Portfolio
  • Licensing Opportunities
  • Investors
Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • 2022 Annual General Meeting
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Legend Removal
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Nov 01, 2022 9:25am EDT

Lexaria Receives Independent Review Board Approval for its Upcoming Human Oral Nicotine Study

Oct 27, 2022 8:45am EDT

Lexaria's Human Clinical Hypertension Study a Success

Sep 02, 2022 9:15am EDT

Lexaria Welcomes Dr. Catherine Turkel to its Board of Directors

Aug 31, 2022 9:05am EDT

Lexaria Receives New Patent in Mexico

Aug 11, 2022 9:15am EDT

Lexaria Discusses Valuation Metrics for Biotech Industry

Aug 11, 2022 8:30am EDT

Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment Solution

Aug 10, 2022 8:15am EDT

Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension

Aug 09, 2022 8:30am EDT

Lexaria Bioscience Corp. (NASDAQ: LEXX) Developing Powerful Tech to Treat Hypertension

Jul 27, 2022 9:10am EDT

Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events

Jul 26, 2022 9:05am EDT

Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 20
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

250.765.6424
info@lexariabioscience.com

Lexaria Bioscience Corp.
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

Privacy Policy

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More

Copyright ©2023 All rights reserved.

Back to the top